UNITED STATES PATENT AND TRADEMARK OFFICE	E
BEFORE THE PATENT TRIAL AND APPEAL BOARD	)
CELLTRION, INC., Petitioner,	
V.	
REGENERON PHARMACEUTICALS, INC., Patent Owner.	
Case No. IPR2022-00257	
Petitioner,  v.  REGENERON PHARMACEUTICALS, INC., Patent Owner.	

MOTION FOR JOINDER UNDER 35 U.S.C. § 325(c) AND 37 C.F.R. §§42.22 AND 42.222(b)



# I. STATEMENT OF THE PRECISE RELIEF REQUESTED

Petitioner, Celltrion, Inc. ("Celltrion" or "Petitioner"), respectfully requests joinder of the concurrently filed petition for *inter partes* review of U.S. Patent No. 9,669,069 ("the '069 Patent") (IPR2020-00257) with *Mylan Pharms. Inc. v. Regeneron Pharms., Inc.*, IPR2021-00880 (P.T.A.B.), filed May 5, 2021 and instituted on November 10, 2021 ("the Mylan IPR"). (*See* IPR2021-00880, Paper 21.) Celltrion has conferred with Mylan, and Mylan, including the real parties-in-interest identified in its petition, does not oppose this Motion for Joinder.

The instant Petition is substantially the same as the Mylan IPR: it involves the same patent, same claims, same grounds of unpatentability, and the same evidence (including the same prior art combinations supported by the same expert declarations) as the Mylan IPR. If joined Celltrion will assume a "silent understudy" role and will not take an active role in the *inter partes* review proceeding unless the Mylan Petitioner ceases to participate in the instituted IPR. Thus, the proposed joinder will neither unduly complicate the Mylan IPR nor delay its schedule. As such, the joinder will promote judicial efficiency in determining patentability in the Mylan IPR without prejudice to Patent Owner.

Although Celltrion is not otherwise time barred pursuant to 37 C.F.R. § 42.101(b), this Motion for Joinder, and accompanying Petition, are timely because they are filed less than one month after a decision instituting trial in the



Mylan IPR. 37 C.F.R. § 42.122(b) ("no later than one month after the institution date of any inter partes review for which joinder is requested."). Accordingly, Celltrion respectfully requests that the Board grant this Motion for Joinder.

## II. STATEMENT OF REASONS FOR RELIEF REQUESTED

### A. Legal Standard

The Leahy-Smith America Invents Act (AIA) permits joinder of *inter partes* review (IPR) proceedings. Joinder is governed by 35 U.S.C. § 315(c), which states:

(c) JOINDER. – If the Director institutes an inter partes review, the Director, in his or her discretion, may join as a party to that inter partes review any person who properly files a petition under section 311 that the Director, after receiving a preliminary response under section 313 or the expiration of the time for filing such a response, determines warrants the institution of an inter partes review under section 314.

The AIA's legislative history makes clear that joinder is to be liberally granted. 157 Cong. Rec. S1376 (daily ed. Mar. 8, 2011) (statement of Sen. Kyl). As joinder should be liberally granted, the factors *General Plastic Indus. Co. Ltd.* v. Canon Kabushiki Kaisha, IPR2016-01357, Pap. 19 at 16 (Sept. 6, 2017) favor



institution, as Celltrion has not previously filed a petition challenging the same claims of the '069 patent.<sup>1</sup>

A motion for joinder should "(1) set forth the reasons why joinder is appropriate; (2) identify any new grounds of unpatentability asserted in the petition; (3) explain what impact (if any) joinder would have on the trial schedule for the existing review; and (4) address specifically how briefing and discovery may be simplified." *Dell Inc. v. Network-1 Sec. Solutions, Inc.*, IPR2013-00385, Paper 17 (PTAB July 29, 2013); *Hyundai Motor Co. v. Am. Vehicular Scis. LLC*, IPR2014-01543, Paper 11, at 3 (Oct. 24, 2014); *Macronix Int'l Co. v. Spansion*, IPR2014-00898, Paper 15, at 4 (Aug. 13, 2014) (quoting *Kyocera Corp. v. Softview LLC*, IPR2013-00004, Paper 15, at 4 (April 24, 2013)).

<sup>&</sup>lt;sup>1</sup> The other factors are either also positive or neutral. For example, Factor 6, which is the "finite resources of the Board," favors institution as Celltrion is advancing the same challenges, arguments, and evidence relied upon in the Mylan IPR. For the same reason, Regeneron's Preliminary Response was not used as a roadmap for this Petition. And as discussed in the Motion, joinder would have no impact on the trial schedule for the Mylan IPR.



## B. Celltrion's Motion for Joinder is Timely

A motion for joinder is timely if the moving party files within one month of institution of the inter partes review for which joinder is requested. 37 C.F.R. 42.122(b). Because Celltrion files this motion within one month after a decision on the institution of the Mylan IPR, this motion is timely.

# C. Joinder is Appropriate

Joinder is appropriate because Celltrion's Petition does not raise any new grounds of unpatentability and does "not present issues that might complicate or delay" the Mylan IPR. *See Enzymotec Ltd. v. Neptune Techs & Bioresources, Inc.*, IPR2014-00556, Paper 19 (PTAB July 9, 2014). Celltrion's Petition is substantially identical to the petition in the Mylan IPR, challenging the same claims of the '069 Patent on the same grounds and relying on the same expert testimony. Thus, the only difference between Celltrion's Petition and the petition filed in the Mylan IPR are the sections on Real Party-In-Interest, Related Matters, and Counsel, which have been appropriately updated.

Joinder would, therefore, have little, if any, impact on the Mylan IPR, the schedule would not be affected, no additional briefing or discovery would be required, and no additional burdens would be placed on any party or the PTAB, as detailed below.



# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

# **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

# **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

# **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

## **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

